Imophoron Announces Grant of Key ADDomer Technology Patent in Japan
Granted patent provides exclusivity for ADDomer-based treatments until 2037
BRISTOL, UK – 22 October 2024 – Imophoron, a biopharmaceutical company specialising in thermostable nanoparticle vaccines through its ADDomer™ platform, today announced the Japan Patent Office's (JPO) recent grant of a pivotal patent.
The patent entitled “Adenoviral coat protein-derived delivery vehicles”, is exclusively licensed to Imophoron from CNRS (Centre National de la Recherche Scientifique) and EMBL (European Molecular Biology Laboratory) and encompasses fundamental claims related to the use of multiple ADDomer scaffolds for vaccine development. Notably, the period of exclusivity extends until 2037, providing Imophoron with a robust foundation for continued innovation.
Richard Bungay, Chief Executive Officer of Imophoron, commented: “We are thrilled to announce the grant of our pivotal technology patent in Japan. Building on our recent successes in securing patents in the US and Europe, we now have a strong exclusivity position across the three largest pharmaceutical markets globally. This significant achievement enhances our ability to lead the development of thermostable vaccines, which have the potential to revolutionise treatments for viral infections and address other critical healthcare challenges.”
For further information, please visit www.imophoron.com or contact:
Richard Bungay, Chief Executive Officer
About Imophoron
Founded in 2017, Imophoron specialises in thermostable nanoparticle vaccine development through its proprietary ADDomer platform. The ADDomer technology offers a disruptive approach to combating infectious diseases and has potential applications in oncology. The platform allows for rapid insertion of epitopes into a single thermotolerant particle, enabling the development of thermostable, multivalent vaccines to address high unmet medical needs.
​